Doxorubicin–Trabectedin with Trabectedin maintenance in Leiomyosarcoma
Vivek Subbiah shared a post on X about a recent paper by Patricia Pautier et al., commenting:
“Doxorubicin–Trabectedin with Trabectedin maintenance in Leiomyosarcoma, New England Journal of Medicine.
Work from our colleagues across the other side of Atlantic from the French Sarcoma Group and Gustave Roussy, PharmaMar, Inserm.
150 patients underwent randomization. med Overall Survival (OS) doxorubicin–trabectedin is 33 months versus doxorubicin group 24 months.
Progressive Free Survival (PFS) doxorubicin–trabectedin group is 12 months versus doxorubicin group is 6 months
What would Robert Benjamin say?”
Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma published in The New England Journal of Medicine.
Additional information
Source: Vivek Subbiah/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023